Igor Bondarenko

57.6k total citations · 16 hit papers
317 papers, 17.7k citations indexed

About

Igor Bondarenko is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Igor Bondarenko has authored 317 papers receiving a total of 17.7k indexed citations (citations by other indexed papers that have themselves been cited), including 243 papers in Oncology, 144 papers in Pulmonary and Respiratory Medicine and 55 papers in Cancer Research. Recurrent topics in Igor Bondarenko's work include Cancer Treatment and Pharmacology (69 papers), HER2/EGFR in Cancer Research (64 papers) and Lung Cancer Treatments and Mutations (61 papers). Igor Bondarenko is often cited by papers focused on Cancer Treatment and Pharmacology (69 papers), HER2/EGFR in Cancer Research (64 papers) and Lung Cancer Treatments and Mutations (61 papers). Igor Bondarenko collaborates with scholars based in United States, Ukraine and Russia. Igor Bondarenko's co-authors include Dennis J. Slamon, Carsten Bokemeyer, P. Koralewski, Filippo de Braud, Martin Reck, Angela Zubel, Yaroslav Shparyk, Gunter Schuch, Xin Huang and Anatoly Makhson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Igor Bondarenko

303 papers receiving 17.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

2014 1.4k citations Richard S. Finn, John Crown et al. The Lancet Oncology profile →
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

2016 1.2k citations Massimo Cristofanilli, Nicholas C. Turner et al. The Lancet Oncology profile →
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

2008 1.2k citations Igor Bondarenko et al. Journal of Clinical Oncology profile →
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

2012 816 citations Igor Bondarenko et al. Journal of Clinical Oncology profile →
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

2018 777 citations Nicholas C. Turner, Dennis J. Slamon et al. profile →
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

2011 766 citations Igor Bondarenko, Joyce O’Shaughnessy et al. Journal of Clinical Oncology profile →
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

2014 694 citations Igor Bondarenko et al. The Lancet Oncology profile →
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

2011 612 citations Igor Bondarenko et al. profile →
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

2012 592 citations Igor Bondarenko, Ihor Vynnychenko et al. Journal of Clinical Oncology profile →
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

2012 500 citations Igor Bondarenko et al. profile →
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

2010 453 citations Igor Bondarenko, Р. Ш. Хасанов et al. Journal of Clinical Oncology profile →
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

2016 384 citations J.F.R. Robertson, Igor Bondarenko et al. profile →
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

2021 244 citations Ihor Vynnychenko, Igor Bondarenko et al. profile →
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

2023 183 citations Eric Van Cutsem, Igor Bondarenko et al. profile →
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

2022 151 citations Yi‐Long Wu, Dariusz M. Kowalski et al. Journal of Clinical Oncology profile →
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

2022 114 citations Massimo Cristofanilli, Seock‐Ah Im et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Igor Bondarenko

Since Specialization

Citations

This map shows the geographic impact of Igor Bondarenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor Bondarenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor Bondarenko more than expected).

Fields of papers citing papers by Igor Bondarenko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Igor Bondarenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor Bondarenko. The network helps show where Igor Bondarenko may publish in the future.

Co-authorship network of co-authors of Igor Bondarenko

This figure shows the co-authorship network connecting the top 25 collaborators of Igor Bondarenko. A scholar is included among the top collaborators of Igor Bondarenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Igor Bondarenko. Igor Bondarenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer 2025 ·Clinical Cancer Research ·Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova, Erika Hamilton, Yoichi Naito, (unknown), Igor Bondarenko, Toshinari Yamashita, Li Zhou, (unknown), (unknown), (unknown), Feng Liu, Jennifer Park, Maria Delioukina, Komal Jhaveri	5
2	Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial 2025 ·Journal of Clinical Oncology ·J.F.R. Robertson, Zhimin Shao, Shinzaburo Noguchi, Igor Bondarenko, Lawrence Panasci, Sandeep Singh, S. Shankar, Matthew J. Ellis	3
3	Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study 2025 ·Margarita Majem, Enric Carcereny, Bernard Doger, Timothy Clay, Igor Bondarenko, Julio A. Peguero, Manuel Cobo, Martin Förster, Ewa Kalinka‐Warzocha, (unknown), Laia Vilà, Wade T. Iams, Matthew Krebs, Begoña Campos, Christian Mueller, (unknown), Frédéric Triebel	0
4	OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC) 2024 ·Journal of Thoracic Oncology ·Hidehito Horinouchi, Benjamin Solomon, Yi‐Long Wu, (unknown), Matomo Nishio, Jin Seok Ahn, D.H. Lee, J.-S. Lee, Wen‐Zhao Zhong, Maximilian J. Hochmair, Igor Bondarenko, (unknown), Achim Rittmeyer, Beiying Ding, Thorsten Ruf, (unknown), Astrid Scalori, Rafał Dziadziuszko	1
5	CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2024 ·Journal of Clinical Oncology ·Neeraj Agarwal, Arun Azad, Joan Carles, Nobuaki Matsubara, Stéphane Oudard, Fred Saad, Axel S. Merseburger, Andrey Soares, Bradley A. McGregor, Bogdan Żurawski, Scott North, Marinos Tsiatas, Igor Bondarenko, (unknown), (unknown), Keerti Vardhan Sharma, (unknown), Roberta Ferraldeschi, Fong Wang, Sumanta K. Pal	20
6	Ipatasertib plus Paclitaxel for Patients with PIK3CA / AKT1 / PTEN -Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial 2024 ·Clinical Cancer Research ·Rebecca Dent, Sung‐Bae Kim, Mafalda Oliveira, Carlos H. Barrios, Joyce O’Shaughnessy, Steven J. Isakoff, Shigehira Saji, Ruffo Freitas‐Júnior, (unknown), Igor Bondarenko, Qinshu Lian, Denise Bradley, Heather Hinton, Matthew Wongchenko, (unknown), Nicholas C. Turner	9
7	Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study 2024 ·Clinical Cancer Research ·Niels Reinmuth, Óscar Juan, Dariusz M. Kowalski, Maciej Bryl, Anna Kryzhanivska, (unknown), Zsolt Horváth, Gabriella Gálffy, Eszter Csánky, Zsolt Pápai Székely, Ihor Vynnychenko, J. Armstrong, Tapashi Dalvi, Mingchao Xie, Sonia Iyer, Yashaswi Shrestha, Haiyi Jiang, Igor Bondarenko	5
8	A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma 2023 ·ESMO Open ·Byoung Chul Cho, Konstantin Penkov, Igor Bondarenko, (unknown), Joanna Pikiel, Hee Kyung Ahn, (unknown), M. A. Osipov, (unknown), Fadi Braiteh, Antoni Ribas, Juneko E. Grilley‐Olson, Iwona Ługowska, Vinícius Bonato, (unknown), (unknown), (unknown), (unknown), (unknown), Melissa L. Johnson	4
9	Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial 2021 ·BioDrugs ·Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yuee Teng, Xichun Hu, Igor Bondarenko, Hryhoriy Adamchuk, Liangming Zhang, Dmytro Trukhin, Shusen Wang, Hong Zheng, Zhongsheng Tong, Yaroslav Shparyk, Qingyu Wang, (unknown)	28
10	Distance learning: opportunities and challenges in quarantine. 2020 ·SHILAP Revista de lepidopterología ·(unknown), Igor Bondarenko, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	5
11	PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study 2018 ·British Journal of Cancer ·Mark D. Pegram, Igor Bondarenko, (unknown), (unknown), Hirotaka Iwase, Petr Krivorotko, Keun Seok Lee, Rubi K. Li, Joanna Pikiel, Rajesh Aggarwal, Reginald B. Ewesuedo, Amy Freyman, Ray Li, (unknown), Donghua Yin, Charles Zacharchuk, Elizabeth Tan-Chiu	50
12	systemic-treatment-of-breast-cancer-depending-on-bmi-using-l-carnitine/# 2017 ·(unknown), Igor Bondarenko, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
13	Body mass index as a prognostic feature in breast cancer 2017 ·Journal of Cancer Science & Therapy ·Igor Bondarenko, (unknown)	0
14	A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis 2016 ·Clinical Cancer Research ·Robert E. Hawkins, Martin Gore, Yaroslav Shparyk, (unknown), Oleg Gladkov, (unknown), Mihai Hârza, (unknown), Igor Bondarenko, Petr Karlov, O. B. Kаryakin, Р. Ш. Хасанов, Gunnar Hedlund, G. Forsberg, Örjan Nordle, Timothy Eisen	23
15	Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients 2016 ·Supportive Care in Cancer ·Constantin Volovăț, Igor Bondarenko, Oleg Gladkov, Anton Buchner, (unknown), Udo Müller, Peter Bias	7
16	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 2016 ·Breast Cancer Research ·Richard S. Finn, John Crown, Johannes Ettl, Marcus Schmidt, Igor Bondarenko, István Láng, Tamás Pintér, Katalin Boér, Ravindranath Patel, Sophia Randolph, Sindy T. Kim, Xin Huang, Patrick Schnell, Sashi Nadanaciva, Cynthia Huang Bartlett, Dennis J. Slamon	136
17	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial breakdown → 2016 ·The Lancet Oncology ·Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Ke Zhang, Kathy Puyana Theall, Yuqiu Jiang, Cynthia Huang Bartlett, María Koehler, Dennis J. Slamon	1247
18	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study breakdown → 2014 ·The Lancet Oncology ·Richard S. Finn, John Crown, István Láng, Katalin Boér, Igor Bondarenko, (unknown), Johannes Ettl, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, (unknown), Camilla Fowst, Xin Huang, Sindy T. Kim, Sophia Randolph, Dennis J. Slamon	1412
19	Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III) 2012 ·Journal of Clinical Oncology ·Hans‐Joachim Schmoll, David Cunningham, Alberto Sobrero, Christos S. Karapetis, Philippe Rougier, Sheryl Koski, Ilona Kocáková, Igor Bondarenko, G. Bodoky, Paul N. Mainwaring, Ramón Salazar, Peter Barker, Bijoyesh Mookerjee, Jane Robertson, Eric Van Cutsem	163
20	Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer 2012 ·Journal of Clinical Oncology ·Antonio C. Wolff, Ann Lazar, Igor Bondarenko, August Garin, Stephen Brincat, Louis W.C. Chow, Yan Sun, Zora Nešković‐Konstantinović, Rodrigo C. Guimarães, P. Fumoleau, Arlene Chan, (unknown), Andrew Strahs, Maria Cincotta, Anna Berkenblit, Mizue Krygowski, (unknown), Laurence Moore, Daniel F. Hayes	222

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact